Controlling Particle Size and Release Kinetics in the Sustained Delivery of Oral Antibiotics Using pH-Independent Mucoadhesive Polymers by Yus, C. et al.
Controlling Particle Size and Release Kinetics in the Sustained
Delivery of Oral Antibiotics Using pH-Independent Mucoadhesive
Polymers
Cristina Yus, Silvia Irusta, Victor Sebastian,* and Manuel Arruebo*
Cite This: https://dx.doi.org/10.1021/acs.molpharmaceut.0c00408 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: Copolymers synthesized from acrylic acid and methacrylic acid used as gastroprotective and mucoadhesive enteric
coatings have been used to prepare micro- (∼2 μm), submicro- (∼200 nm), and nanoparticles (∼20 nm) containing rifampicin (Rif)
to obtain time-controlled drug release kinetics. Different particle sizes and drug release kinetics have been obtained using different
synthesis conditions and fabrication techniques including the use of an electrosprayer and an interdigital microfabricated micromixer.
The antimicrobial action of the encapsulated Rif has been demonstrated against Staphylococcus aureus ATCC 25923 and compared
with the effect of the equivalent dose of the free macrolide antibiotic. At low concentrations, the encapsulated antibiotic showed
superior antimicrobial activity than the free drug. The stability of the developed particles has been evaluated in vitro under simulated
gastric and intestinal conditions. At the concentrations tested, a reduced cytotoxicity against different human cell lines was observed
after analyzing their subcytotoxic doses and the influence on their cell cycle by flow cytometry. Drug release kinetics can be tuned by
adjusting particle sizes, and it would be possible to reach the minimum inhibitory concentration or the minimum bactericidal
concentration at different time points depending on the medical needs.
KEYWORDS: Eudragit, drug delivery, size-dependent release kinetics, Staphylococcus aureus, antimicrobial activity, rifampicin,
cytocompatibility
■ INTRODUCTION
Antimicrobial delivery systems have been developed to provide
therapeutic doses at predetermined rates above the minimum
bactericidal concentration (MBC) and below the maximum
toxicological threshold. Extended-release dosage forms main-
tain sufficient antibiotic plasma concentration and promote
patient compliance, improving the therapeutic index. Fur-
thermore, antibiotic encapsulation in biodegradable matrices
prolong the duration of hydrophobic biocides, while reducing
unwanted side effects. In this regard, Sung et al.1 demonstrated,
in preclinical models, that the encapsulation of rifampicin
(Rif), one of the first-line antituberculotic antibiotic, within
poly(lactic-co-glycolic acid) (PLGA) nanoparticles provided a
prolonged presence in the lungs. A sevenfold dose sparing was
demonstrated by Lueth et al.2 when comparing the bacterial
counts present in Brucella melitensis-infected mice from animals
treated with a weekly dose of doxycycline-encapsulated
nanoparticles and with the daily dose of the free drug.
Antibiotic-associated adverse side effects might include
hemolytic activity and cytotoxicity against mammalian cells.
However, the encapsulation of several antimicrobials within
nanoparticulated carriers can alleviate these side effects. In this
regard, Li et al.3 confirmed that the cytotoxicity of ciprofloxacin
against HeLa cells and the hemolytic activity of an
antimicrobial copolymer can be reduced when encapsulated
within polymeric nanoparticulated vesicles. Hussain et al.4
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demonstrated not only that nanoencapsulated vancomycin was
10-fold more effective than free vancomycin in a Staphylococcus
aureus-induced pneumonia model in vivo but also they proved
the lack of toxicity to the liver. Reduced cytotoxicity against
mammalian cells has also been reported when conjugating Rif
to nanoparticulated carriers in the eradication of intracellular
pathogens (Mycobacterium tuberculosis) in coculture models.5
Encapsulation can also provide antibiotics with enhanced
bioavailability and protection from physiological degradation.
In this regard, increased skin penetration, reduced haemolytic
activity, and a lack of cytotoxicity against mammalian cell lines
were reported in a methicillin-resistant S. aureus (MRSA)-
infected burn-wound animal model when using chloramphe-
nicol-loaded poly(epsilon-caprolactone) (PCL)-Pluronic nano-
particles compared to the administration of the free antibiotic.6
Several antibiotics have been gastroprotected to prevent their
degradation during the presystemic metabolism, improving
their bioavailability. Antibiotic-mixed matrices and amorphous
solid dispersions with gastroprotective materials or their
encapsulation as thin coatings on the active principle have
been included in the formulations to overcome these
limitations. For instance, clarithromycin has been protected
with carboxyl-containing cellulose derivatives, forming nano-
particles to quench the acid-catalyzed degradation in the
stomach and improve the aminomacrolide antibiotic solubility
in the intestine.7 Likewise, cellulose derivatives have also been
used to protect rifapentine from gastric degradation and to
improve its reduced solubility at intestinal pH.8 According to
Singh et al., 26.5% of free Rif was degraded using simulated
gastric fluid (SGF) with its degradation aggravated under the
presence of one of the secondary antibiotics used (isoniazid) as
common combination therapy.9 Conversely, its encapsulation
in solid lipid nanoparticles prepared by microemulsification has
been demonstrated to reduce its degradation by threefold.9
Compared to the oral administration of the free drug in
preclinical models, improved pharmacokinetics (i.e., area under
the concentration−time curve and mean residence time) have
also been achieved by encapsulating Rif within gelatin-based
nanoparticles.10 Not only lipids, polymers, and polysaccharides
of natural origin are used to obtain gastroprotection but also
synthetic polymers can be used to take advantage of their
ability to produce time-controlled drug release to specific
anatomical areas in the intestinal lining. Copolymers of methyl
acrylate, methyl methacrylate, and methacrylic acid are used to
avoid gastric degradation and to achieve pH-dependent or pH-
independent intestinal delivery of encapsulated antibiotics.
Some of them are pH-dependent and remain protonated and
insoluble in the stomach but dissolve in the intestine; others
are mucoadhesive in the intestinal lining and being insoluble,
they erode over time providing with a time-controlled targeted
release of the encapsulated active principle. We have previously
encapsulated Rif within pH-dependent methacrylate-based
microparticles (i.e., Eudragit L100-55) and demonstrated
their antibiotic protection against SGF, being the active
antibiotic able to cross an in vitro model of the intestinal
barrier.11 Compared to the oral administration in human
subjects of the free drug and the equivalent dose of Rif
encapsulated in Eudragit S100, a superior bioavailability and
sustained release were demonstrated for the latter.12 The
gastroprotection of Rif in these carriers cannot only protect the
drug from the acidic oxidative degradation but also improve its
bioavailability, overcoming its reduced water solubility (2.5
mg/mL at 25 °C, pH 7.3). Protecting the cargo against
degradation and providing with a timely drug release at a
specific anatomical location in the digestive tract would be
ideal to maximize active drug absorption.
Rif is an antimycobacterial agent that also inhibits
ribonucleic acid synthesis in a wide range of other microbial
pathogens. Because of its rapid development of bacterial
resistance, it is commonly used in combination with other
antimycobacterial agents (isoniazid, pyrazinamide, and etham-
butol). Implant-associated infections have also been treated in
vivo with Rif as combination therapy in the successful
eradication of multidrug-resistant (MDR) Gram-negative
bacteria colonizing catheters13 and Gram-positive bacteria
(i.e., MRSA) colonizing infected coverslips used as models of
implant-associated infections.14 S. aureus has also been used as
a model of pathogen having part of its life cycle intracellularly.
In this regard, Sandberg et al.15 demonstrated, using a murine
peritonitis/sepsis model, that Rif was able to eliminate both
intracellular and extracellular bacteria, and compared with
other four antibiotics (i.e., dicloxacillin, cefuroxime, gentami-
cin, and azithromycin), Rif showed the highest antimicrobial
effect extracellularly. Three randomized controlled trials and
one cohort reported on adults diagnosed with S. aureus
bacteraemia (SAB) revealed that Rif in combination with
standard β-lactam or glycopeptide therapy might produce an
improved clinical outcome in SAB treatment.16 S. aureus-
associated chronic osteomyelitis has also been treated in vivo
with Rif because this wide-spectrum antibiotic has been
demonstrated to be superior when reducing bacterial loads
compared to β-lactams, fluoroquinolones, vancomycin, line-
zolid, daptomycin, fosfomycin, gentamicin, and clindamycin.17
With S. aureus biofilms formed on implants as a model of
osteomyelitis, Jørgensen et al.18 also confirmed its superior
antimicrobial action in vivo alone or in combination when
compared to vancomycin, daptomycin, and linezolid. However,
further standardized double-blinded randomized clinical trials
are required to justify the use of Rif because adverse drug
interactions and the appearance of Rif resistance may
overshadow its demonstrated benefits in the treatment of S.
aureus-associated infections.19
Therefore, gastroprotection and targeted delivery to improve
absorption and systemic distribution of Rif might improve its
pharmacokinetics in the treatment of S. aureus-associated
infections. In this work, we have used the pH-independent and
mucoadhesive Eudragit RS100 (EuRS100) polymer as a drug
carrier to encapsulate the antimycobacterial agent Rif. As a
novelty, we have demonstrated that particle size and drug
loadings can be adjusted by selecting the proper fabrication
process. Finally, we have varied the physical properties of the
Rif-loaded carriers in order to control drug release kinetics and
achieve an effective and timely antimicrobial action to
potentially prevent S. aureus (ATCC 25923)-associated
infections. In addition, the mucoadhesive character of the
carrier on the intestinal lining would allow a sustained release
of the antimicrobial cargo over time to provide with a
therapeutic dose. This release can be tunable depending on the
needs by properly selecting the particle size and structure.
■ EXPERIMENTAL SECTION
Materials. EuRS100 was generously donated by Evonik
Industries AG (Essen, Germany). Chloroform (anhydrous,
≥99%), acetone (>99%), dimethyl sulfoxide (DMSO, > 99%),
Rif (≥ 97%), and phosphate-buffered saline (PBS) were
purchased from Sigma-Aldrich (Darmstadt, Germany). Etha-
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nol absolute (EtOH) was purchased from PanReac AppliChem
(Barcelona, Spain). All reagents were used as received without
any further purification. SGF (HCl 0.1 N, NaCl and H2O, pH
= 1.1) without enzymes was prepared according to the US
Pharmacopoeia XXIII (1995).
S. aureus (ATCC 25923) was purchased from Ielab
(Alicante, Spain). Tryptone soy broth (TSB) and tryptone
soy agar were purchased from Laboratorios Conda-Pronadisa
SA, (Torrejon de Ardoz, Spain). Caco2-TC7 clone human
epithelial colorectal adenocarcinoma cells were kindly donated
by Dr. M.J. Rodriguez Yoldi. Human dermal fibroblasts were
obtained from Lonza (Bornem, Belgium). High-glucose
Dulbecco’s modified Eagle’s medium (DMEM; DMEM w/
stable glutamine) and antibiotic−antimycotic (60 μg/mL
penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL
amphotericin B) were supplied by Biowest (Nuaille,́ France),
supplemented with 10% (v/v) fetal bovine serum (FBS) from
Gibco (Thermo Fisher Scientific, Waltham, Massachusetts,
USA). Blue cell viability assay was purchased from Abnova
(Abnova GmbH, Taipei, Taiwan).
Synthesis of Nano- and Microparticles. Depending on
the particle size desired, two fabrication techniques were used,
namely, electrospraying and nanoprecipitation. The electro-
sprayed particles were synthesized in a Yflow 2.2.D-500
electrospinner (Electrospinning Machines/R&D Microencap-
sulation, Valencia, Spain) by the action of electro-hydro-
dynamic forces. The initial polymer solutions were composed
of 13% (w/v) EuRS100 in chloroform and 3% (w/v) EuRS100
in EtOH/acetone (1:1). For Rif encapsulation, an adequate
amount of antibiotic [15 and 20% (w/w) referred to the
amount of EuRS100 added] was added to the precursor
polymer solution, and the final solution was sonicated for 10
min. The corresponding Rif-EuRS100 solutions were intro-
duced into a 10 mL syringe connected to a 22G needle, and
the flow rate was set at 0.5 mL/min. A flat collector was used
to collect the resulting particles, and the distance between the
tip and the collector was set at 10 cm. The positive voltage
applied to the needle was 6.4 kV for EuRS100 13% (w/v) and
12.5 kV for EuRS100 3% (w/v), and the negative voltages
applied to the collector were −3.4 and −4.7 kV, respectively.
Particles were synthesized at room temperature with a relative
humidity between 30 and 50%. The collector was covered with
aluminum foil. After spraying, the produced microparticles
were gently scratched from the foil.
Nanoprecipitated particles were obtained in a commercial
polyether ether ketone (PEEK)-based interdigital microfluidic
device (Micro4 Industries GmbH, Mainz, Germany), de-
scribed elsewhere.20 Polymer solutions of 5% (w/v) EuRS100
in EtOH/acetone (1:1) and 5% (w/w) of Rif referred to
EuRS100 were used as solvent phases. The antisolvent phase
consisted of milliQ water. Both phases were introduced into
two syringes, and the total flow rate was set at 5 mL/min using
syringe pumps (Harvard Apparatus, Holliston, MA, USA), and
the flow rate antisolvent/solvent ratio was set at R = 5. Solvent
and antisolvent phases were interfaced in the interdigital
micromixer. The nanoprecipitated particles were collected at
the outlet of the micromixer and were evaporated at room
temperature under magnetic stirring (600 rpm) until the
removal of the organic solvents.
Particle Characterization. Particle morphology was
studied using an Inspect F50 field emission gun scanning
electron microscope. Samples were Au/Pd-coated (Leica EM
ACE200, Leica, Wetzlar, Germany) to allow electrical
observation. Particle size diameter was determined using
ImageJ software (Version 1.48f, NIH, USA) (N = 150), and
size distribution was analyzed by statistical analysis. The
morphology and size distribution of the samples were also
characterized by transmission electron microscopy (TEM,
T20-FEI Tecnai thermoionic transmission electron micro-
scope, Hillsboro, OR, USA). For TEM observation, samples
were stained with phosphotungstic acid as negative contrast,
following a previous protocol of our group.21 The hydro-
dynamic diameter and Z-potential value of the colloidal
particles at neutral pH were determined by dynamic light
scattering measurements using a Brookhaven 90 Plus (Holts-
ville, NY, USA) equipment. Each sample was measured three
times.
Rif encapsulation efficiency (EE) and drug loading of the
electrosprayed particles were determined by UV−vis spec-
trophotometry (Jasco V670, Jasco Applied Science, Eschborn,
Germany) at a wavelength of 340 nm by dissolving 2 mg of
Rif-loaded particles in 1 mL of DMSO using three independent
samples. At the wavelength of study, no polymer interference
was observed. The EE and drug loading (DL) were calculated
with eqs 1 and 2, respectively
EE (%)
mass of entrapped drug (mg)




mass of entrapped drug (mg)
total mass of particles (mg)
100= ×
(2)
Rif EE and DL of nanoprecipitated particles were calculated
by an indirect quantification. The collected nanoparticles were
washed several times with milliQ water using an Amicon Ultra-
15 centrifugal filter unit with 30 kDa cutoff. Supernatants were
collected, and nonentrapped Rif was measured by UV−vis. EE
(eq 1) and DL (eq 2) were calculated by considering the
entrapped Rif as the difference between the total Rif added and
the nonentrapped Rif in a mass balance.
Fourier-transform infrared (FTIR) spectra were recorded to
evaluate if drug−polymer molecular interactions occur. FTIR
spectra were obtained using a Bruker VERTEX 70 FTIR
spectrometer (Bruker, Billerica, MA, USA) equipped with a
Golden Gate diamond ATR accessory. Spectra were recorded
by averaging 40 scans in the 4000−600 cm−1 wavenumber
range at a resolution of 4 cm−1. Data evaluation was carried out
using OPUS software from Bruker Optics.
An X-ray diffractometer (Empyrean, Malvern Panalytical,
Malvern, UK) was used to record the X-ray diffraction (XRD)
diffractograms of the different samples. The measuring
conditions were as follows: 2θ angle ranging from 5 to 50
deg with a scan rate of 0.017°/s and a step size of 0.013°.
Particle stability under simulated gastric and intestinal
conditions was analyzed using the paddle method under sink
conditions. The corresponding particles were suspended in
SGF without enzymes (0.1 N HCl, pH 1.1 at 37 °C, 2 h). The
particles were also immersed in intestinal simulated fluid (PBS,
pH 7.4 at 37 °C) without enzymes, and their stability and
morphology were analyzed by scanning electron microscopy
(SEM) at different time points (2 h, 24 h, 25 days, and 60
days). Those long times were selected due to the
mucoadhesive character of the microparticles, they do not
dissolve at a specific pH, they are pH-independent, and they
slowly erode releasing their contained cargo.
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In vitro Drug Release Study. The in vitro release of Rif
from the corresponding particles was performed under sink
conditions by introducing 5 mg of particles in 5 mL of SGF
during 2 h. Afterward, particles were centrifuged for 10 min at
13,300 rpm, and the supernatant was replaced with PBS 1× (5
mL) to simulate intestinal conditions. Particles were incubated
at 37 °C under continuous mixing, and at predetermined time
intervals (0, 0.5, 1, 2, 4, 6, and 8 h and 1 to 75 days), 1 mL of
the supernatant was collected by centrifugation for 5 min at
13,300 rpm and an equal volume of fresh PBS was replenished.
To collect the supernatants of microfluidic-produced particles,
an Amicon Ultra-15 centrifugal filter unit with 30 kDa cutoff
was used. Four different samples were independently analyzed.
In PBS, the potential degradation of the drug at long times is
minimized (see Figure S3).
Bacterial Culture and Viability Analysis. To determine
the antimicrobial activity of the different particles, the
minimum inhibitory concentration (MIC) and the MBC of
the free antibiotic (Rif) were evaluated using S. aureus (ATCC
25923) as a model of a Gram-positive infective pathogen.
Bacteria were grown overnight in TSB at 37 °C under
continuous shaking, 150 rpm. When bacteria were grown at the
stationary growth phase (1010 cfu/mL), they were diluted in
TSB until reaching 105 cfu/mL. The inoculum was placed into
an eppendorf tube with a specific quantity of Rif (0−1 ppm)
dissolved in DMSO. A toxicity control using only DMSO was
also performed in parallel. After 24 h, at 37 °C and 150 rpm,
the standard serial dilution method was used to determine
viable bacteria. Positive control (untreated bacteria) was also
included in the study and analyzed as reported.
The same protocol detailed to determine MIC and MBC
values was here considered to evaluate the antimicrobial effect
of the Rif-containing particles. A bacterial inoculum of 105 cfu/
mL was placed with different particle dispersion concentrations
(1−0.005 mg/mL), and the serial dilution method was again
used. Each experiment was performed in triplicate with four
replicas for each sample using independent syntheses.
Cell Culture and Viability Analysis. Caco2-TC7 human
epithelial colorectal adenocarcinoma cells and human dermal
fibroblast were used to evaluate the potential cytotoxic effect of
EuRS100 and Rif-EuRS100 particles. Caco2 and fibroblast cells
were cultured in high-glucose DMEM supplemented with 10%
(v/v) FBS and 1% (w/v) antibiotic−antimycotic at 37 °C in a
humidified atmosphere with 5% CO2. Cytotoxicity was
measured analyzing the cell metabolism using the Blue cell
viability assay according to the manufacturer’s instructions.
Briefly, cells were seeded into 96-well plates, allowed to attach
and proliferate until confluence, and treated with empty
particles, Rif-containing particles, and comparative doses of the
free antibiotic. Particles were tested at concentrations between
1 and 0.005 mg/mL, and the free antibiotic at the measured
value of Rif concentration released after 24 h from each
particle was also evaluated for 24 h at 37 °C and 5% CO2. After
incubation, cells were washed several times to remove particles
from the wells. Then, cells were incubated with the reagent
[10% (v/v) in DMEM] and incubated for 3 h at 37 °C.
Fluorescence was measured at 530/590 nm excitation/
emission wavelengths in a Multimode Synergy HT microplate
reader (Biotek, WI, USA). Cell viability was determined by
comparing the values retrieved for the treated cells and the
Figure 1. (a,b) SEM image and size distribution retrieved from SEM measurements of EuRS100 microparticles (electrospray), (c,d) SEM image
and size distribution of Rif-loaded EuRS100 microparticles (electrospray), (e,f) SEM image and size distribution of empty EuRS100 sub-
microparticles (electrospray), (g,h) SEM image and size distribution of Rif-loaded EuRS100 sub-microparticles (electrospray), (i,j) TEM image
and size distribution of empty EuRS100 nanoparticles (nanoprecipitation), and (k,l) TEM image and size distribution of Rif-loaded EuRS100
nanoparticles.
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untreated controls which were assigned with 100% viability.
Each determination was performed in triplicate having four
replicas in each experiment, using independent syntheses.
The subcytotoxic dose was reached when the viability of cell
lines was reduced more than 30% (subcytotoxic concen-
tration). At this dose, the effect of the particles on the cell
membrane was determined by the study of cell apoptosis by
flow cytometry. After treating the cells with the particles, cells
were exhaustively washed and stained with annexin V-FITC
and propidium iodide. Finally, stained cells were incubated for
15 min and then analyzed in a Facsaria BD equipment. Data
were evaluated using Facsdiva BD software. Control samples
with untreated cells were also analyzed to determine the
influence of the particles on cell apoptosis. The cell cycle at
subcytotoxic concentrations was also analyzed. After treatment,
cells were collected in PBS and fixed in 70% cold ethanol and
stored at 4 °C for 24 h. Then, samples were treated with
RNase A, and DNA was stained with propidium iodide.
Samples were measured in a Facsarray BD equipment with
Modifit 3.0 Verity software. Control samples having untreated
cells were also analyzed to determine the influence of the
particles on the cell cycle.
Table 1. Encapsulation Efficiency (%), Drug Loading (%), and Z-Potential (mV) of Electrosprayed Rif-Loaded Microparticles,
Electrosprayed Rif-Loaded Sub-Microparticles, and Rif-Loaded Nanoparticles Obtained by Microfluidic Nanoprecipitation
EE (%) drug Loading (mg rif/mg particle) drug loading (%) Z-potential (mV)
EuRS100 13%−ES 99.3 ± 1.6 0.13 ± 0.003 13.0 ± 0.3 +28.9 ± 2.6
EuRS100 3%−ES 82.9 ± 1.0 0.14 ± 0.002 14.0 ± 0.2 +23.9 ± 2.7
EuRS100 5%−NP 42.3 ± 2.4 0.02 ± 0.001 2.0 ± 0.1 +17.4 ± 2.2
Figure 2. a) XRD diffractograms and (b) FTIR spectra of unloaded EuRS100 microparticles, sub-microparticles, and nanoparticles; Rif-loaded
microparticles, sub-microparticles, and nanoparticles, and free Rif.
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Statistical Analysis. All results are expressed as mean ±
standard deviation (SD). Two-way analysis of variance
(ANOVA) was used to analyze bacterial and cellular
experiments (GraphPad Prism 7, San Diego, USA). Statistically
significant differences were considered when p ≤ 0.05.
■ RESULTS
Physicochemical Characterization of the Particles.
Using two different fabrication techniques (i.e., electrospraying
and nanoprecipitation) and varying the solvents (acetone,
ethanol, and chloroform) and polymer concentrations, three
different particle sizes in the nano-, submicro-, and microscale
were able to be produced using EuRS100. An initial battery of
solvents, polymer concentrations used in the polymeric
precursor solution, and Rif concentrations was screened in
order to optimize the corresponding syntheses and obtain high
DL and reduced particle polydispersity (optimization results
not shown). Figure 1a,b shows the SEM image and size
distribution of empty microparticles made with EuRS100 13%
(w/v) in chloroform obtained by electrospraying, having a
uniform particle size distribution centered at 2.6 ± 0.4 μm.
When Rif was incorporated (15% w/w) in the same
formulation, similar sizes (2.7 ± 0.5 μm) and particle
monodispersity were also maintained (Figure 1c,d). To reduce
the particle sizes of EuRS100 formulations, we considered to
(1) use a mixture of ethanol and acetone instead of using
chloroform in order to increase solvent polarity and (2) reduce
the EuRS100 polymer concentration in the precursor solution.
Figure 1e,f shows the SEM image and size distribution of
empty microparticles made with EuRS100 3% (w/v) in EtOH/
acetone obtained by electrospraying, also having a uniform
submicron particle size distribution centered at 271.1 ± 57.3
nm. When Rif was incorporated (20% w/w) in the same
formulation, similar sizes (224.3 ± 73.5 nm) and particle
monodispersity were also obtained (Figure 1g,h). Finally, in
order to obtain particles in the nanoscale range, nano-
precipitation using miscible solvents in a commercial
interdigital micromixer was used. Figure 1i,j shows the SEM
image and size distribution of empty nanoparticles made with
EuRS100 5% (w/v) in EtOH/acetone obtained by micro-
fluidic-assisted nanoprecipitation, having a uniform particle
size distribution centered at 18.4 ± 5.5 nm. When Rif was
incorporated (5% w/w) into the same formulation, similar
sizes (17.7 ± 5.0 nm) and particle monodispersity were also
obtained (Figure 1k,l).
In electro-hydrodynamic spraying, flash solvent evaporation
takes place during the flight between the needle tip and the
collector caused by the high volatility of the organic solvents
used, whereas the polymer precipitates trapping the associated
drug. However, during nanoprecipitation, because of the
miscibility of the solvent and antisolvent, part of the entrapped
drug diffuses with the organic solvent during solvent
displacement, and at the same time, the polymer starts to
precipitate, trapping the remaining drug because of its
immiscibility in the antisolvent phase. For this reason, Rif
loadings (Table 1) obtained for the micro- (13 ± 0.3%) and
sub-microparticles (14 ± 0.2%) by electrospraying were higher
than the ones measured for the nanoparticles (2 ± 0.1%)
obtained in the microfluidic mixer. These results are according
to those reported in the previous literature where higher EE
was obtained when particle sizes increased.22 Likewise, drug
encapsulation efficiencies for the particles obtained by
electrospraying were at least double than the ones obtained
when using the nanoprecipitation method (42.3 ± 2.4%). In
the production of the electrosprayed particles when using a
reduced polymer concentration (RS100 3%, w/v), the EE
(82.9 ± 1%) was lower than the one obtained when using high
polymer concentration RS100 13% (w/v) (99.3 ± 1.6%),
probably because of a reduced mixture viscosity and because of
drug evaporation during the electrohydrodynamic synthesis
Figure 3. Rif release from (a) electrosprayed Rif-loaded EuRS100 microparticles, (b) electrosprayed Rif-loaded EuRS100 sub-microparticles, and
(c) nanoprecipitated Rif-loaded EuRS100 nanoparticles. SEM images of Rif-loaded EuRS100 carriers at different release times under SGF (the first
2 h) and SIF (afterward): (d) electrosprayed Rif-loaded EuRS100 microparticles, (e) electrosprayed Rif-loaded EuRS100 sub-microparticles, and
(f) nanoprecipitated Rif-loaded EuRS100 nanoparticles.
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process. The zeta potential for the colloidal suspensions of the
obtained particles in water was largely positive because of the
presence of 5% of functional quaternary ammonium groups in
the EuRS100, which confers mucoadhesive properties.23 This
positive charge facilitates particle interaction with the
negatively charged acidic amino acids (i.e., aspartic acid and
glutamic acid) and acidic monosaccharides (i.e., sialic acid)
present in the intestinal mucus.24
XRD diffractograms and FTIR spectra of Rif and the
different particles are shown in Figure 2. Peaks at 9.9 and 11.3°
in Rif XRD diffractogram (Figure 2a) indicate that the used
drug was in the polymorphic form II. This was confirmed by
FTIR analysis, where the Rif spectrum shows bands at 1734,
1712, and 1567 cm−1 (Figure 2b) related to furanone CO,
acetyl CO, and amide CO, respectively, characteristic of
form II Rif.25 The small band at 2883 cm−1 related to N−CH3
vibration can also be observed. Loaded particle XRD
diffractograms do not show any peak that could be related to
a crystalline form of Rif. Even when this fact could be due to
the presence of amorphous drug inside the particles, the
absence of signals could also be related to the presence of drug
crystals smaller than 40 Å and/or because the Rif load is below
the technique detection limit. The broad band observed in
particle diffractograms confirms the amorphous nature of the
polymer.26,27 Loaded and unloaded particle FTIR spectra have
a characteristic peak at 1726 cm−1, assigned to the EuRS100
CO ester vibration.28 No peak related to Rif can be observed
in loaded nanoparticle spectra, while a small band observed
around 1566 cm−1 would be related to the presence of Rif in
micro- and sub-microparticles. The amide CO vibration
band appears at almost the same wavelength for Rif forms I
and II (1567 and 1566 cm−1, respectively), and as a
consequence, it is impossible to know, from this peak, the
polymorphic form of Rif in the particles or even their
crystallinity. The absence of Rif signals in the FTIR
nanoparticle spectrum could be due to the low drug loading
achieved by the nanoprecipitation technique.
Drug Release Kinetics and Morphological Analysis
under Simulated Enteric Conditions. Cumulative drug
release kinetics placing the particles under simulated gastric
conditions for 2 h followed by intestinal simulated fluid
conditions (up to 60 days) are depicted in Figure 3. After 2 h
of contact in SGF, only (2.1 ± 0.2%), (2.8 ± 0.6%), and (6.5 ±
3.5%) of the drug were released from the Rif-loaded EuRS100
microparticles (∼2 μm), EuRS100 sub-microparticles (∼200
nm), and EuRS100 nanoparticles (∼20 nm), respectively. A
homogenous particle surface free of cracks or pinholes might
be responsible for this protection under SGF (Figure S1). The
smaller the particle size, the faster the Rif release in both SGF
and simulated intestinal fluid (SIF). In this regard, Rif-loaded
EuRS100 nanoparticles (∼20 nm) showed a burst release with
almost 89% released after 24 h. EuRS100 sub-microparticles
(∼200 nm) released almost 51% of their contained drug in 75
days, whereas the EuRS100 microparticles (∼2 μm) released
42% of the encapsulated drug in the same time period. For
microparticles, different from nanoparticles, the small surface
area per unit volume leads to a reduced rate of water
permeation. Specifically, the surface to volume ratio in 20 nm
nanoparticles (0.3 nm−1) is 100-fold larger than that in 2 μm
microparticles (0.003 nm−1). Then, the limited diffusivity in
the polymeric matrix reduces the maximum possible rate of
encapsulated Rif release. As a result, Rif is released in a time-
controlled manner from the pH-independent low-permeability
mucoadhesive particles, and their different sizes allow reaching
pharmacokinetic control. Therefore, having the same polymer,
by just modifying the particle size, drug release kinetics can be
tuned depending on the needs. The EuRS100 nanoparticles
(∼20 nm) would provide with a fast antibiotic release, and the
larger EuRS100 submicron (∼200 nm) or microparticles (∼2
μm) would provide time-dependent sustained release.
Drug release data of all the particles synthesized were fitted
using different mathematical models including Korsmeyer-
Peppas, Higuchi, Peppas−Sahlin, Lindner-Lippold, zero-order,
and first-order kinetics (Figure S2).
The best fit for the EuRS100 submicron particles (∼200
nm) and microparticles (∼2 μm) synthesized by electro-
spraying was observed for the Peppas−Sahlin model (Table
S1),29 where K1 is the kinetic constant related to the diffusional
contribution, K2 is the kinetic constant related to the case-II
polymer relaxation contribution, and the coefficient n is related
to the diffusion type. In this case, diffusional mechanism
predominates over the relaxation of polymer chains (K1 ≫ K2).
The negative values obtained for K2 would be related to the
insignificant contribution of relaxation mechanisms compared
to the diffusion process.30 In both cases, n was lower than 0.43,
the expected value for Fickian diffusion from spherical
geometries. Similar results were previously attributed to the
effect of different particle size distributions.31 The best fit for
the particles obtained with the microfluidic nanoprecipitated
EuRS100 nanoparticles (∼20 nm) was observed for the
Lindner−Lippold model (Table S1),32 where k is a release
constant related to the release rate, n is the coefficient related
to the release mechanism, and b is the constant characteristic
of the burst effect. When drug diffusion and polymer erosion
control the release process in equal parts, the value of n in the
Lindner−Lippold model takes a value of 0.62, and higher
values of n are attributed to an increase in erosion-driven
control. In our case, n = 0.7 would imply a slight predominance
of erosion on the release process.
Figure 3d−f shows the morphology of the corresponding
Rif-loaded EuRS100 particles after simulated gastric and
intestinal conditions. SEM micrographs demonstrate their
morphological stability under simulated gastric conditions (0.1
N HCl, pH 1.1 at 37 °C, 2 h), corroborating their ability to
withstand an acidic environment. Under simulated intestinal
conditions (PBS, pH 7.4 at 37 °C for 24 h), the particles slowly
swelled and eroded, increasing their permeability. Different
behaviors were observed for the particles after 25 and 60 days
under these conditions, depending on the formulation. Despite
the nonbiodegradable nature of these polycationic acrylic
polymers, the EuRS100 when formulated as nanoparticles
(∼20 nm) after being immersed for 7 days under simulated
intestinal conditions formed plasticized agglomerations.
Submicron particles (∼200 nm) initially swelled and eroded,
and after 25 and 60 days under these conditions, they
agglomerated and formed heterogeneous plasticized films. At
the same time points, EuRS100 microparticles (∼2 μm) still
preserved most of their initial morphology, although incipient
agglomeration and irreversible aggregation took place.
Even when some erosion could be observed in micro-
particles and sub-microparticles, this effect is not strong
enough to lead drug release, and for these particles, a diffusion-
controlled process was observed. On the other hand,
nanoparticles are more affected by the neutral medium
because of their high surface per volume ratio, causing the
observed burst release and rapid release kinetics.
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Antimicrobial Activity and Cytocompatibility. These
materials were challenged against S. aureus ATCC 25923 to
corroborate that the activity of Rif was still preserved after
encapsulation. MIC and MBC values for free Rif were
calculated using the standard broth microdilution method. It
can be observed that the MIC was reached at 0.05−0.125 μg/
mL, whereas the MBC was reached for concentrations in the
0.25−0.5 μg/mL range, in agreement with the previous
literature.33,34 Comparing the antibacterial effect in the
inhibition of ribonucleic acid synthesis of the free drug and
the equivalent doses of the EuRS100-encapsulated Rif, the
particles and the free drug showed the same antibacterial
activity at high doses (>0.1 mg/mL for the particles which
correspond to a free antibiotic released concentration of >1.3
μg/mL in 24 h) independent of their sizes (Figure 4).
However, at low concentrations (between 0.001 and 0.01 mg/
mL for the particles, which correspond to a free antibiotic
released concentration in 24 h between 0.01 and 0.1 μg/mL), a
superior antimicrobial effect was observed for the encapsulated
micro- (∼2 μm) and sub-microparticles (∼200 nm), probably
promoted by a contact effect by the electrostatic interaction
between the particle (positive superficial charge) and the
Figure 4. Antibacterial activity of (a) electrosprayed Rif-loaded EuRS100 microparticles, (b) electrosprayed Rif-loaded EuRS100 sub-
microparticles, and (c) Rif-loaded EuRS100 nanoprecipitated nanoparticles. The control sample was assigned to the untreated bacteria. Data are
presented as mean ± SD (n = 3). (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).
Figure 5. (a-c) Cell viability in the Caco2-TC7 cell line of (a) electrosprayed Rif-loaded EuRS100 microparticles, (b) electrosprayed Rif-loaded
EuRS100 sub-microparticles, and (c) nanoprecipitated Rif-loaded EuRS100 nanoparticles. (d−f) Cell viability in the fibroblast cell line of (d)
electrosprayed Rif-loaded EuRS100 microparticles, (e) electrosprayed Rif-loaded EuRS100 sub-microparticles, and (f) nanoprecipitated Rif-loaded
EuRS100 nanoparticles. 100% viability was assigned to the untreated control cells. Data are presented as mean ± SD (n = 3). (*p < 0.05, **p <
0.01, ***p < 0.001, and ****p < 0.0001).
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bacteria (negatively charged cell wall). For the EuRS100, when
formulated as nanoparticles (∼20 nm), a similar antimicrobial
effect was observed for the free and for the encapsulated
antibiotics in these low-range concentrations. The parent
EuRS100 particles nonloaded with the antibiotic did not
display any antimicrobial action at the doses tested. Therefore,
the results shown in Figure 4 would infer that particle doses as
low as 0.1 mg/mL for the microparticles (∼2 μm), the sub-
microparticles (∼200 nm), and the nanoparticles (∼20 nm)
would be needed to reach MBC.
The same doses of the empty and Rif-loaded EuRS100
particles were also evaluated using human cell lines (Caco-2,
Human Caucasian colon adenocarcinoma cell line and human
dermal fibroblasts) in order to corroborate the reduced toxicity
of the materials at the doses that produced a complete bacterial
eradication. It can be observed (Figure 5a−c) that no cytotoxic
effect was observed for any of the particles tested at
concentrations below 1 mg/mL for Caco-2 cells having
viability percentages higher than 70%, but it is important to
highlight that at these concentrations, a bactericidal effect was
observed (Figure 4). However, the treatment of fibroblasts,
assayed (Figure 5d−f) with micro- and sub-microparticles at a
concentration of 1 mg/mL, affected cell viability with
percentages of 57.4% for microparticles and 66.7% for sub-
microparticles, but no effect was observed for the nanoparticles
at the doses tested (Figure 5c).
Following the recommendations of the ISO 10993-5, in
which viability percentages below 70% are considered
cytotoxic, we selected a concentration of 1 mg/mL to
corroborate the non-cytotoxicity of the submicron particles
and microparticles, evaluating the effect of the Rif-loaded
particles on the cell cycle arrest and potential apoptosis
induction. As it can be seen in Figure 6, no significant
differences compared to the untreated controls were observed
for the particle-treated cells independently if the particles were
loaded with the Rif or not. Compared to the controls, an
increase in the G2 phase (i.e., rapid cell growth and synthesis of
proteins preceding mitosis) of the cell cycle was observed for
the Rif-loaded particles. The results showed that no DNA
damage or cell cycle arrest was observed for Rif-loaded
microparticles (Figure 6 a) and sub-microparticles (Figure 6b)
in the fibroblasts.
By comparing the apoptosis induction of the empty and Rif-
loaded particles (1 mg/mL) on the fibroblasts with the
nontreated cells, the effect of the particles on the cell
membrane was evaluated (Table 2). Necrosis showed an
increase lower than 6%, while apoptosis showed a maximum
increase of 2.65% for the Rif-loaded microparticles. Never-
theless, apoptosis percentage displayed a decrease of up to
7.73% for the rest of the particles tested. Rif-loaded and
unloaded submicron particles and microparticles did not exert
cytotoxic effects; hence, the reduction on cell viability for a
concentration of 1 mg/mL was probably caused by
experimental manipulation. Previous studies have shown the
absence of cytotoxic effects of EuRS100 particles on SW480
cell lines (colon adenocarcinoma cell line)35 and on HCEpC
cell lines (human corneal epithelial cells) at a concentration of
100 μg/mL.36 Cell viabilities over 80% for Caco-2 cell lines at
a concentration of up to 20 mg/mL of EuRS100 microparticles
were also reported.37 In other studies, in vitro Rif treatment
was not harmful on HepG2 cell lines (liver hepatocellular
carcinoma),38 neither on primary murine macrophages.39
However, it has been reported that at high doses reached by
systemic administration, Rif may be detrimental to cell
proliferation of osteogenic cells.40
Pharmacokinetic Control on Drug Release. Finally, we
wanted to demonstrate that using the different Rif-loaded
particles developed, it was possible to reach MIC or MBC at
different time points depending on the needs. We used the
required amounts of EuRS100 nanoparticles (∼20 nm),
submicron particles (∼200 nm), and microparticles (∼2 μm)
that contain the same amount of Rif (0.05 mg) in all cases.
Figure 6. Cell cycle assay in the fibroblast cell line of (a) electrosprayed EuRS100 microparticles and (b) electrosprayed EuRS100 sub-
microparticles. G1 (first growth phase), S (DNA replication phase), and G2 (growth phase). Control samples (not treated cells) were analyzed as
the background cell cycle level.
Table 2. Cell Apoptosis Evaluation by Flow Cytometry after Treatment with Rif-Loaded Microparticles and Sub-











viability 76.9 81.7 76.6 78.5% 78.5
early apoptosis 4.3 3.6 8.5 4.1 4.4
late apoptosis 14.9 9.57 13.3 13.5 7.1
necrosis 3.9 5.05 1.5 3.8 9.9
aControl samples (not treated cells) were analyzed as the background apoptosis level.
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://dx.doi.org/10.1021/acs.molpharmaceut.0c00408
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
I
With this aim, 2.5 mg of EuRS100 nanoparticles (∼20 nm),
0.36 mg of EuRS100 submicron particles (∼200 nm), and 0.39
mg of EuRS100 microparticles (∼2 μm) were placed in 10 mL
of PBS simulating intestinal fluid at 37 °C. Figure 7b shows
that using the EuRS100 when formulated as nanoparticles
(∼20 nm), the MBC can be reached in only 0.3 h, whereas
with the submicron EuRS100 particles (∼200 nm), the same
MBC concentration is reached in 14.5 h, and with the
EuRS100 microparticles (∼2 μm), this concentration can be
reached after 40.6 h. Figure 7c also shows that concentrations
above the MIC can be reached in only 0.09 h when using small
EuRS100 nanoparticles (∼20 nm), whereas with the
submicron EuRS100 particles (∼200 nm), it would be reached
after 1 h, and with the EuRS100 microparticles (∼2 μm), it
would be reached after 1.9 h.
■ DISCUSSION
The high drug entrapments observed can be attributed to the
supramolecular interactions (i.e., induced dipole interactions)
between the aromatic rings in Rif and the quaternary
ammonium salts in EuRS100.41 As we mentioned before, the
flash evaporation of the solvent in the flight form the needle to
the collector is responsible for the high drug loadings observed
for the electrosprayed micro- and sub-microparticles. However,
because of the slight water solubility (2.5 mg/mL, at 25 °C and
pH 7.3) of the Rif, attributed to the polar groups in the
molecule (two on the napthol ring and three on the ansa
bridge42), the loss of Rif during the aqueous nanoprecipitation
process in the two miscible solvents (water and ethanol/
acetone) rendered lower drug loadings (2.0 ± 0.1 wt %).
When using the electrospraying technique, flash organic
solvent evaporation in the flight from the needle to the
collector reduces the drug loss, whereas when using the
nanoprecipitation technique, the diffusion of the organic
solvent through the interface of the formed droplets is a
slow process, which contributes to a partial loss of the
encapsulated drug during the polymer precipitation process.
Likewise, the nanoparticles obtained by nanoprecipitation are
washed after synthesis to remove all the nonencapsulated
drugs, and thanks to their large surface area per volume ratio,
part of the drug is also lost. These reasons can explain the
differences on the encapsulation efficiencies observed for the
electrosprayed particles compared to the nanoparticles
obtained by nanoprecipitation. Despite this reduced drug
loading, the release from the nanoparticles under simulated
intestinal conditions was very rapid (Figure 3), which would
overcome the large limitation of reduced water solubility for
Rif and its reduced bioavailability being a class II drug in the
biopharmaceutics classification system.43
Another advantage of using these micro- and nano-
particulated antibiotic carriers is that the residence time in
the stomach would be shorter than the one obtained from
conventional solid oral dosage forms having larger sizes (e.g.,
tablets or capsules) and, therefore, the acidic degradation of Rif
(∼26.5%9) would be reduced. The large surface area per
volume ratio available in the micro- and nanoparticles would
also reach homogeneously a large surface area in the intestinal
lining instead of providing with a local release from the
conventional solid oral dosage forms.
Most of the previous publications in which Rif is
gastroprotected aim to obtain an improved drug solubility
and a fast drug release in the stomach because under acidic
conditions, the drug solubility increases, being principally
absorbed in the stomach and duodenum.43,44 Herein, we show
that different drug release kinetics can be obtained under
simulated intestinal conditions, avoiding gastric degradation.
Hydroxypropyl cellulose alone and in combination with pH-
dependent Eudragit L100-55 have been used in the fabrication
of matrix tablets containing Rif and isoniazid.45 Even though
these authors showed that Rif solubility was ∼40 times higher
under acidic conditions, Eudragit was also included in the
formulation to achieve gastroprotection and to promote drug
release in the intestine for up to 24 h. However, in this case,
the polymer completely dissolves at pH 5.5 by salt formation,
releasing the contained cargo completely. In our vehicle, a
sustained pH-independent drug release is achievable. A similar
polymer (Eudragit RL100) was used by Ammar and Khalil12 to
coencapsulate paracetamol and Rif prepared by coevaporation
of the solvent containing the acrylic polymer together with the
drugs. In this case, a microparticulate (250 μm) mixed matrix
was obtained after grinding and sieving the drug and polymer
together in order to analyze the influence of the polymer in the
drug dissolution rates under simulated gastric and intestinal
conditions. Using this vehicle, 60% of the drug was solubilized
in only 8 h.
Several in vivo studies have demonstrated the enhanced
efficacy of administering a microencapsulated drug orally in
EuRS100 over the effect of the equivalent dose of the free
drug. For instance, Meena et al.46 demonstrated, in chemically
induced diabetic rats, that EuRS100-based microencapsulated
catechin (a bioflavonoid with efficacy against type-2 diabetes)
daily administered orally for 60 days produces a superior
hypoglycemic effect than the free natural compound. The same
polymer has been used for the microencapsulation (53 μm) of
one of the low-molecular-weight heparins (i.e., nadroparin) in
the oral administration using preclinical models (male adult
New Zealand rabbits) being their anticoagulative effect
compared with the equivalent dose of a commercial
formulation of the free drug subcutaneously (SC) injected.47
Figure 7. (a) Evolution of the relation observed between time and Rif release in the Rif-loaded EuRS100 carriers developed in this work, (b) time
to reach MBC, and (c) time to reach MIC.
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Plasmatic anticoagulation activity was maintained at the same
level than the one achieved after SC administration, but high
relative bioavailabilities (up to 40%) were achieved when using
the microparticulated form.
Furthermore, the particles developed in our work would be
largely excluded from reaching the systemic circulation because
of their mucoadhesive nature caused by the positively charged
quaternary ammonium groups in addition to the dense
thickness of the mucus which varies from ∼123 μm in the
jejunum to ∼830 μm in the colon.48 In addition, because of the
intercellular tight junction, complexes present in the intestinal
epithelium macromolecules above 1 nm are largely excluded to
percolate.49 Therefore, the microparticles would be largely
excluded to be absorbed intact through the intestinal wall. In a
potential envisaged application, these formulations would be
orally administered as a suspension bypassing gastric
degradation, attaching to the intestinal wall, eroding slowly
in a time-controlled manner, and releasing their cargo.
As we mentioned before, a sustained antimicrobial action of
antibiotics against infections caused by S. aureus is required in
different scenarios including implant-associated infections,
indwelling medical devices, and chronic osteomyelitis. We
showed that the encapsulation in the acrylic polymers of the
model antibiotic did not impair its antibacterial action (Figure
4). The prevalence of periprosthetic infection is established in
1−2% for total hip and knee arthroplasties, and in revision
surgeries, the values for infected replacements increase to 5−
40%, whereas for fixation devices on open fractures, the
infection incidence exceeds 30%.50,51 Because of the small size
of the EuRS100 nanoparticles (∼20 nm) achievable, a burst Rif
release is observed under neutral pH, and consequently, the
antimicrobial action is similar to the effect observed for the free
drug (Figure 4). Nevertheless, for the submicron EuRS100
(∼200 nm) and microparticles (∼2 μm), a superior
antimicrobial effect was observed, probably caused by the
combination of the mucoadhesive character of the positively
charged polymer, which electrostatically interacts with the
negatively charged bacterial wall, and the time-dependent
sustained release achieved, promoting antibiotic intracellular
transport.
The reduced cytotoxicity observed on mammalian cell lines
for the different empty and Rif-loaded particles prepared in this
work (Figure 5) is also corroborated in previous studies.52,53
According to the pharmacopeia,12 a daily intake of 2−200 mg/
kg bodyweight depending on the grade of Eudragit is
considered as largely safe in humans. In addition, the lack of
cytotoxicity against eukaryotic cells, also observed for Rif even
at the maximum dose tested (21 μg/mL), is in agreement with
the previous literature.54 IC50 for Rif on human fibroblasts has
been reported for doses one order of magnitude higher than
the ones used in this work.55 A reduced S phase and increased
G1 and G2 phases observed for the empty and Rif-loaded
particles compared to the untreated control would be an
indication of a slight cell cycle arrest. Although slight
differences were observed, cellular viability was not affected
at the subcytotoxic dose studied. In summary, at the doses
studied, neither the acrylic polymers used nor the antibiotic
induced cytotoxicity on human cells.
As we have shown, using different synthesis conditions, we
are able to obtain gastroprotected antibiotic-loaded particles
having tunable drug release kinetics. In some antibiotic
therapy, a fast-systemic distribution is needed, whereas in
other infections, a long-term antibiotic treatment is desirable.
Chronic infections (e.g., pressure or diabetic foot ulcers),
recurrent urinary tract infections, chronic respiratory diseases,
infections associated with intracellular pathogens (e.g., tuber-
culosis), implant-associated infections, and primary and
secondary prophylaxis are usually managed with long-term
antibiotic therapy. Fast releasing systems are necessary in acute
infections, in prophylaxis (e.g., in wounds, burns, joint
replacements, C-sections, etc.), and also in the management
of endogenous diseases (e.g., sepsis, urinary tract infections,
skin and soft tissue infections, etc.). A prolonged release would
be desirable in chronic communicable diseases (e.g., tuber-
culosis, respiratory and healthcare bacterial infections, etc.).
Herein, we have demonstrated that using different synthesis
protocols, we can produce antibiotic-loaded particles that can
provide with a burst or prolonged release over time and reach
antimicrobial levels at different time points.
A recent study of Klein et al.56 showed that despite the
preventive campaigns to spread awareness on antibiotic
resistance, the antibiotic use in 76 countries studied over 16
years (2000−2015) increased by 65% (expressed as prescribed
daily doses), and the antibiotic consumption rate increased by
39%. Therefore, the development of controlled antibiotic
releasing systems which provide the required antimicrobial
concentration without underdosing or overdosing for the
specific acute or chronic infections represents an advantage
compared to the uncontrolled systemic therapy and provides
with a rational usage of drugs.
■ CONCLUSIONS
Time-controlled release pH-independent polymers have been
used in the synthesis of Rif-loaded nano-, submicro-, and
microparticles using electrospraying and micromixing-assisted
nanoprecipitation−solvent evaporation techniques. The differ-
ent particle sizes allow producing a burst or a long-term
antibiotic release, reaching MICs and MBCs in the hour or day
range depending on the needs. The encapsulation of the
antibiotic did not impair its antimicrobial action against Gram
positive bacteria. At low concentrations, the encapsulated
antibiotic showed superior antimicrobial action compared to
the equivalent doses of the free wide-spectrum antibiotic. The
polymeric carriers and resulting antibiotic-loaded particles did
not produce cytotoxic effects on human cell lines or significant
cell arrests after analyzing the cell cycles. The developed
materials are promising vectors to provide the correct
antibiotic doses according to the type of infection.
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